Ipatasertib

帕他色替

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameIpatasertib
Drug Alias NameIpatasertibum艾他舍替Ipatasertib DihydrochlorideRG-7440GCD-0068 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursParanasal Sinus Diseases +[36] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArray BiopharmaGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteFoundation Medicine IncRoche Pharma Ag +[14] 
Inactive CompaniesIcahn School Of Medicine At Mount Sinai
Active IndicationsMetastatic breast cancerSolid tumoursParanasal Sinus Diseases +[33] 
Inactive IndicationsHepatic InsufficiencyStomach NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG